Nevirapine Aurobindo (Nevirapine)

Nevirapine inhibits the HIV‑1 reverse transcriptase enzyme by binding to a non‑nucleoside site, causing a conformational change that blocks the conversion of viral RNA into DNA. This interruption of the replication cycle reduces viral load.

The dosage of Nevirapine Aurobindo is determined by the prescribing clinician based on individual patient factors, treatment guidelines, and combination regimen. Patients should follow the exact dosing instructions provided by their healthcare professional.

The safety of Nevirapine in pregnancy and lactation is not fully established. Clinicians must weigh potential benefits against risks and consider alternative therapies when appropriate. Breastfeeding decisions should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nevirapine belongs to the NNRTI class, which directly inhibits reverse transcriptase at a non‑nucleoside site. Compared with nucleoside reverse transcriptase inhibitors (NRTIs), NNRTIs like Nevirapine often have a different resistance profile and may be combined with NRTIs for synergistic viral suppression.

Nevirapine Aurobindo tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain stability.

Nevirapine Aurobindo is taken orally, usually with food to reduce gastrointestinal irritation. The tablets should be swallowed whole with a full glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, hepatotoxicity leading to liver failure, and hypersensitivity reactions. Patients should be monitored closely for rash, jaundice, fever or other signs of liver injury, and seek immediate medical attention if they occur.

Nevirapine Aurobindo is contraindicated in individuals with a known hypersensitivity to nevirapine or any component of the formulation. It should also be avoided in patients with severe liver disease or a history of severe cutaneous adverse reactions to NNRTIs.